Bausch Health posts Q3 2025 results update

Bausch Health Companies Inc. filed a current report to let investors know it has released its financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Bausch Health Companies Inc. filed a current report to let investors know it has released its financial results for the quarter ended September 30, 2025. On October 29, 2025, the company issued a press release covering its results of operations and other financial information for that quarter, which is included as Exhibit 99.1.

The company states that this information is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and will not be incorporated by reference into securities offering documents. The filing is mainly a formal notice pointing readers to the detailed third-quarter 2025 results contained in the attached press release.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bausch Health Companies Inc. (BHC) disclose in its October 29, 2025 report?

Bausch Health Companies Inc. disclosed that it issued a press release announcing its results of operations and other financial information for the quarter ended September 30, 2025, which is attached as Exhibit 99.1.

Where can investors find Bausch Health (BHC) Q3 2025 financial results?

The detailed financial results for the quarter ended September 30, 2025 are contained in the press release attached as Exhibit 99.1 to the report.

Is the Bausch Health Q3 2025 press release considered filed or furnished under the Exchange Act?

The company specifies that the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Will Bausch Health’s Q3 2025 press release be incorporated by reference into registration statements?

No. The company states that the information in Item 2.02 and Exhibit 99.1 will not be incorporated by reference into any registration statement or other document under the Securities Act.

Does this Bausch Health report or its Q3 2025 press release constitute an offer to sell securities?

No. The company clarifies that the report and the press release do not constitute an offer to sell or the solicitation of an offer to buy any securities.

Who signed the Bausch Health October 29, 2025 report?

The report was signed on behalf of Bausch Health Companies Inc. by Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, as the principal financial officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 04:09 PM Learn about SEC filing dates

0000885590false00008855902025-10-292025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

October 29, 2025

Date of report (Date of earliest event reported)

 Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

British Columbia

,

Canada

001-14956

98-0448205

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Shares, No Par Value			BHC			New York Stock Exchange			Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐            

Item 2.02.     Results of Operations and Financial Condition.

On October 29, 2025, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended September 30, 2025 and certain other financial information as of and for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference. This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 do not constitute an offer to sell or the solicitation of an offer to buy any securities.

The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the “Securities Act”).

Item 9.01.    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.						Description
99.1*						Press Release of Bausch Health Companies Inc., respecting financial results for the third quarter of 2025 dated October 29, 2025
101.SCH*						XBRL Taxonomy Extension Schema Document
101.LAB*						XBRL Taxonomy Extension Label Linkbase Document
101.PRE*						XBRL Taxonomy Extension Presentation Linkbase Document
104*						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

____________________________________

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 29, 2025

			BAUSCH HEALTH COMPANIES INC.
By:			/s/ JEAN-JACQUES CHARHON
			Jean-Jacques Charhon
			Executive Vice President, Chief Financial Officer
			(Principal Financial Officer)